GlobeNewswire by notified

Aduro Clean Technologies Reports Third Quarter 2024 Financial Results

Share

LONDON, Ontario, April 30, 2024 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQX: ACTHF) (FSE: 9D50), a Canadian technology company using the power of chemistry to transform lower value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, has filed its interim consolidated financial results for the three and nine months ended February 29, 2024 and has provided the following highlights. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Ofer Vicus, CEO of Aduro, remarked, “Q3 was a pivotal quarter for the Company as we continued to advance our technology and expand our market presence. The strategic initiatives undertaken not only enhance our technological capabilities but also reinforce our ability to expand our customer engagement program and further our relationships with key stakeholders.”

Mena Beshay, CFO of Aduro, added, “In Q3 we achieved record revenue and maintained a strong cash position. Our financial performance this quarter mirrors the strategic advancements and operational success Aduro has achieved. With our strong financial foundation and continued technological innovation, we are optimally positioned to achieve our goals for 2024 and beyond.”

Third Quarter 2024 - Financial Highlights

  • Quarterly revenue of $103,628 was achieved in Q3 2024, an increase of 78% as compared to revenue of $58,290 generated in Q3 2023.
  • Year-to-date revenue for the nine-months ending February 29, 2024, was $235,266, an increase of 304% as compared to the nine-months ending February 28, 2023.
  • Loss from operations was $2,027,383 for Q3 2024, an increase of 10% as compared to Loss from operations of $1,845,913 in Q3 2023.
  • Property, plant, and equipment carrying cost as at February 29, 2024, was $3.5 million, representing an increase of $132,334 and $848,361 in the three- and nine-months ending February 29, 2024, respectively, signifying an increased investment in research equipment and the completion of the new state-of-the-art laboratory and office facilities located in London, Ontario.
  • The Company maintained a strong cash position of $2,156,359 as at February 29th, 2024.
  • Subsequent to February 29, 2024, the Company received gross proceeds of $2,081,094 from the exercise of warrants and options, further strengthening the Company’s balance sheet.

Third Quarter 2024 - Corporate Highlights and Developments

Strategic Board Appointment: Aduro welcomed Marie Grönborg to its Board of Directors, a seasoned leader with a robust background in sustainable technology. With 30 years of global experience, Ms. Grönborg significantly enhances the diversity and expertise of Aduro's governance structure. Her vast experience as a chemical engineer and former executive in clean-tech industries aligns perfectly with Aduro’s strategic focus on innovation and environmental sustainability. Ms. Grönborg has been a great addition to the board and her leadership is expected to continue to have a profound impact on Aduro’s strategic direction, and in fortifying the Company's position at the forefront of clean technology.

Expansion of Customer Engagement: Building on earlier positive technical evaluation results achieved in the second quarter, a leading Petrochemical Company and confidential participant in the Company’s Customer Engagement Program (CEP) expanded its initial project scope with Aduro. The additional testing included a more diverse range of waste plastic materials, specifically targeting those with higher concentrations of PET, polyurethane, metals, and other challenging contaminants. The decision to expand the initial testing scope highlights the growing interest in our Hydrochemolytic™ technology and the confidence our partners have in the capabilities the Company and its technology platform offer.

Conference Participation: Throughout the third quarter, Aduro actively participated in significant industry events, including the 10th Annual CEM AlphaNorth Capital Event. These events served as excellent platforms for Aduro to highlight its technological advancements, engage with potential investors and partners, and facilitate discussions that are expected to contribute to future collaborations and innovations.

Market Engagement: Aduro's innovative solutions were prominently featured in the Viewpoint with Dennis Quaid documentary series, significantly elevating the profile of its sustainable technologies across a broad audience. The feature was broadcast on over 170 U.S. stations and included a commercial segment aired nationally on the Fox Business Network, showcasing Aduro's commitment to addressing critical environmental challenges through advanced chemical recycling technologies.

Sample Test Results from Continuous Flow Unit: Aduro has achieved significant advancements in the development of its Hydrochemolytic™ Technology through rigorous testing with the continuous flow Plastic reactor. Since its launch in 2023, the reactor has conducted numerous tests on various polypropylene feedstocks, demonstrating exceptional conversion efficiency. The Company shared sample data of test results indicating conversion of up to 95% of the feedstock into valuable hydrocarbon resources, while less than 5% remained unconverted solids or as low value gases. This breakthrough underscores Aduro's potential to enhance the recycling of end-of-life plastics effectively. The reactor test program continues to generate critical data needed to advance the design of the Next Generation Process which remains a major part of Aduro’s strategic goals for 2024.

For a more detailed discussion of Aduro's Q3 2024 results, please refer to the Company's condensed interim consolidated financial statements and interim MD&A for the three and nine months ended February 29, 2024, which are available at www.sedarplus.ca.

About Aduro Clean Technologies
Aduro Clean Technologies is a developer of patented water-based technologies to chemically recycle waste plastics; convert heavy crude and bitumen into lighter, more valuable oil; and transform renewable oils into higher-value fuels or renewable chemicals. The Company’s Hydrochemolytic™ technology activates unique properties of water in a chemistry platform that operates at relatively low temperatures and cost, a game-changing approach that converts low-value feedstocks into 21st-century resources.

For further information, please contact:

Ofer Vicus, CEO
ovicus@adurocleantech.com

Abe Dyck, Investor Relations
ir@adurocleantech.com
+1 226 784 8889

Arrowhead
Thomas Renaud, Managing Director
enquire@arrowheadbid.com
+1 212 619 6889

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future, are forward-looking statements. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Important factors that could cause actual results to differ materially from the Company’s expectations include adverse market conditions and other factors beyond the control of the parties. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events, or otherwise, except as required by applicable law.

The CSE has not reviewed, approved, or disapproved the content of this news release.

To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fa7dd3c1-a211-4dbb-90f6-2f606532ac43

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.21.5.2024 02:25:00 CEST | Press release

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ— Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Hu

IDEX Biometrics – Number of shares in Tranche 1 vs Tranche 2 in the private placement on 15 May 202420.5.2024 23:52:54 CEST | Press release

Reference is made to the stock exchange announcement by IDEX Biometrics ASA (the “Company”) on 15 May 2024 regarding a successful private placement of shares. By inadvertence, the announcement contained a slight error in the allocation of private placement shares between Tranche 1, as issued by the Board pursuant to an authorization to issue shares granted by the extraordinary general meeting dated 21 December 2023, and Tranche 2, to be issued subject to approval by an extraordinary general meeting to be called and scheduled for on or about 12 June 2024. The correct number of Tranche 1 shares is 27,940,213, and the correct number of Tranche 2 shares is 5,393,120, each having a par value of NOK 0.15, with a subscription price of NOK 1.65 per share in the private placement. Consequently, following the issuance of Tranche 1 shares, the Company's share capital is increased with NOK 4,191,031.95 from NOK 42,018,983.25 to NOK 46,210,015.20, and the Company will have 308,066,768 shares issued

INVNT™ ANNOUNCED AS SPONSOR AND CO-PRODUCER OF DISCOVERY STAGE AT SXSW SYDNEY® 202420.5.2024 23:00:00 CEST | Press release

Also named as an endorsed Creative Experiential Partner for the 2024 event Sydney, May 20, 2024 (GLOBE NEWSWIRE) -- INVNT™, the Experiential Disrupter Agency, has today been announced as the sponsor and co-producer of the SXSW Sydney 2024 Discovery Stage after a successful collaboration at last year’s inaugural event. For the second consecutive year, INVNT will bring its world-class expertise in production and innovative brand storytelling and “Challenge Everything” ethos to SXSW Sydney, where it will continue its legacy of hosting, curating and presenting the Discovery Stage and activating across the event’s key pillars of Tech & Innovation, Music, Games and Screen. Featured within the SXSW Sydney Tech & Innovation Expo, the 2024 Discovery Stage will play host to inspiring innovation leaders who are redefining industry norms and will be a place to explore the latest developments in technology and meet startup founders who are poised to disrupt the status quo. As last year’s Discovery

Nokia Corporation: Repurchase of own shares on 20.05.202420.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 20 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 20.05.2024 Espoo, Finland – On 20 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL370,3933.56CEUX--BATE--AQEU--TQEX--Total370,3933.56 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM20.5.2024 20:15:00 CEST | Press release

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decadeand first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS s

HiddenA line styled icon from Orion Icon Library.Eye